跳至主要内容
临床试验/EUCTR2017-000988-32-IT
EUCTR2017-000988-32-IT进行中(未招募)1 期

A Comparative, Open-Label, Randomized, Parallel Group Study to determine Intraperitoneal fluids, tissue, and serum concentrations of VML-0501 following five days of daily vaginal applications of single dose of VML-0501 (100 mg Danazol), in comparison to five days of Danazol treatment administered as an oral capsules (Danatrol) at a daily dose of 600 mg, in two groups of twelve each consisting of women with suspected or confirmed endometriosis and scheduled for laparoscopy. - VML-0501-001

VIRAMAL LIMITED0 个研究点目标入组 24 人开始时间: 2020年11月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • The subject must:
  • Provide written (personally signed and dated) informed consent before completing any study-related procedure, which means any assessment or evaluation that would not have formed a part of her normal medical care.
  • Be a female with signs and symptoms of endometriosis
  • Greater than or equal to 18 years of age and less than 42years.
  • Scheduled to undergo laparoscopy.
  • According to the local practice the women should sign a specific clause on avoiding pregnancy based on the use of two effective methods for birth control (condom and spermicidal) following 30 days after the last dose/application.
  • Be non-pregnant undergoing laparoscopy with signs and symptoms of endometriosis within first 10 days of her cycle.
  • Have a body mass index (BMI) < 32 kg/m2
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 24
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • If any of the following criteria apply, the subject MUST NOT be admitted/continue the study trial.
  • The subject:
  • Is pregnant (if positive-Urine pregnancy test at screening) or lactating;
  • Has evidence of drug or alcohol abuse.
  • Have used hormonal replacement therapy or Danazol therapy within the past 8 weeks before study entry
  • Has any of the following: Epileptic Seizure, Migraine Headache, Angina, Chronic Heart Failure, Obstruction of a Blood Vessel by a Blood Clot, Liver Problems, Kidney Disease, Pregnancy, Combined High Blood Cholesterol and Triglyceride Level, Porphyria
  • Undiagnosed abnormal genital bleeding
  • Androgen dependant tumour
  • Is Allergic to anabolic androgenic steroid.

研究者

相似试验